Neuphoria Therapeutics (B1N0) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| 225 Mg Bnc210 | Social Anxiety Disorder | Phase III | Completed | Efficacy of BNC210 in Acute, As-needed Treatment of Anxiety in Social Anxiety Disorder - 1 | Jul 15, 2024 | ― |
| 225 Mg Bnc210, 675 Mg Bnc210 | Social Anxiety Disorder | Phase II | Completed | A Phase 2 Study of BNC210 for the Acute Treatment of Social Anxiety Disorder | Jan 03, 2022 | ― |
| Bnc210 | Post-Traumatic Stress Disorder | Phase II | Completed | A Phase 2b Study of BNC210 Tablet Formulation in Adults With Post-Traumatic Stress Disorder (PTSD) | Jun 27, 2021 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| 225 Mg Bnc210 | Phase III | Social Anxiety Disorder | Completed | Efficacy of BNC210 in Acute, As-needed Treatment of Anxiety in Social Anxiety Disorder - 1 | Jul 15, 2024 | ― |
| 225 Mg Bnc210, 675 Mg Bnc210 | Phase II | Social Anxiety Disorder | Completed | A Phase 2 Study of BNC210 for the Acute Treatment of Social Anxiety Disorder | Jan 03, 2022 | ― |
| Bnc210 | Phase II | Post-Traumatic Stress Disorder | Completed | A Phase 2b Study of BNC210 Tablet Formulation in Adults With Post-Traumatic Stress Disorder (PTSD) | Jun 27, 2021 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Neuphoria Therapeutics Inc. (DE:B1N0) have in its pipeline
Neuphoria Therapeutics DE:B1N0 is currently developing the following drugs: 225 Mg Bnc210, 225 Mg Bnc210, 675 Mg Bnc210, Bnc210. These drug candidates are in various stages of clinical development as the company works toward FDA approval.